A Raji, EW Seely, SA Bekins, GH Williams, … - Diabetes care, 2003 - Am Diabetes Assoc RESULTS—There was no change in fasting plasma glucose (83 ± 2 vs. 82 ± 2
mg/dl, P = 0.60), but fasting insulin decreased (16.1 ± 1.4 vs. 12.5 ± 0.9
μU/ml, P < 0.01). Total glucose disposal during the clamp increased (5.0 ... Cited by 233 - Related articles - BL Direct - All 8 versions
S Fullert, F Schneider, E Haak, H Rau, K … - Journal of Clinical Endocrinology & Metabolism, 2002 - Endocrine Soc Hypertension is often associated with insulin resistance, dyslipidemia and
obesity, which indicate a prediabetic state and increased risk of cardiovascular
disease. Pioglitazone treatment of patients with type 2 diabetes reduces ... Cited by 118 - Related articles - All 7 versions
G Bakris, G Viberti, WM Weston, M Heise, LE … - Journal of human hypertension, 2003 - nature.com This study examines the effect of rosiglitazone on urinary albumin excretion
(UAE) in patients with type II diabetes. Urinary albumin: creatinine ratio (ACR)
was measured in a 52-week, open-label, cardiac safety study comparing ... Cited by 241 - Related articles - BL Direct - All 3 versions
SMA Bennett, A Agrawal, H Elasha, M Heise, … - Diabetic Medicine, 2004 - interscience.wiley.com Methods Eighteen subjects with persistent IGT were randomized to receive
rosiglitazone 4 mg twice daily or matching placebo for 12 weeks. Evaluation at
baseline and at the end of treatment included measurement of whole body ... Cited by 69 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org M St John Sutton, M Rendell, P Dandona, JF … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Of the 203 patients randomly assigned to RSG (4 mg
bid) or glyburide (GLB) (titrated to achieve optimal glycemic control for the
first 8 weeks only to limit the risk of hypoglycemia; mean 10.5 mg/day), ... Cited by 219 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org N Satoh, Y Ogawa, T Usui, T Tagami, S Kono … - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 136 Japanese type 2 diabetic patients
were included and divided into two groups: the pioglitazone-treated group (30 mg
daily for 3 months) (n = 70) and the untreated control group (n = 66). The ... Cited by 254 - Related articles - BL Direct - All 5 versions
TD Wang, WJ Chen, JW Lin, MF Chen, YT … - The American journal of cardiology, 2004 - Elsevier Fifty nondiabetic patients who met a modified National Cholesterol Education
Program definition for the metabolic syndrome were randomized to receive either
rosiglitazone (4 mg/day; N = 25) or placebo (n = 25) for 8 weeks. Compared ... Cited by 152 - Related articles - All 10 versions
T Ogihara, H Rakugi, H Ikegami, H Mikami, K … - American Journal of Hypertension, 1995 - nature.com The association of hypertension with insulin resistance has been reported.
Troglitazone (CS-045) is a newly developed antidiabetic agent that enhances
insulin sensitivity. Its antidiabetic effects have been confirmed in ... Cited by 242 - Related articles - All 4 versions
PA Sarafidis, AN Lasaridis, PM Nilsson, EM … - Journal of Hypertension, 2004 - journals.lww.com Page 1. Ambulatory blood pressure reduction after rosiglitazone treatment
in patients with type 2 diabetes and hypertension correlates ... Cited by 67 - Related articles - BL Direct - All 5 versions
M Shargorodsky, G Wainstein, E Gavish, Z … - American Journal of Hypertension, 2003 - Elsevier In an open label study 52 patients with non-insulin dependent diabetes mellitus
and at least one additional cardiovascular risk factor, were treated for 6
months with 4 mg of rosiglitazone, and uptitrated to 8 mg after 3 months of ... Cited by 52 - Related articles - All 6 versions
